A Synthetic Multivalent Lipopeptide Derived from Pam3CSK4 with Irreversible Influenza Inhibition and Immuno‐Stimulating Effects
Source abstract
Abstract
Abstract The activation of the host adaptive immune system is crucial for eliminating viruses. However, influenza infection often suppresses the innate immune response that precedes adaptive immunity, and the adaptive immune responses are typically delayed. Dendritic cells, serving as professional antigen‐presenting cells, have a vital role in initiating the adaptive immune response. In this study, an immuno‐stimulating antiviral system (ISAS) is introduced, which is composed of the immuno‐stimulating adjuvant lipopeptide Pam3CSK4 that acts as a scaffold onto which it is covalently bound 3 to 4 influenza‐inhibiting peptides. The multivalent display of peptides on the scaffold leads to a potent inhibition against H1N1 (EC50 = 20 nM). Importantly, the resulting lipopeptide, Pam3FDA, shows an irreversible inhibition mechanism. The chemical modification of peptides on the scaffold maintains Pam3CSK4's ability to stimulate dendritic cell maturation, thereby rendering Pam3FDA a unique antiviral. This is attributed to its immune activation capability, which also acts in synergy to expedite viral elimination.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immune Response and Inflammation · Influenza Virus Research Studies · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Materials École Polytechnique Fédérale de Lausanne Station 12 Lausanne CH‐1015 Switzerland
Department of Microbiology and Molecular Medicine University of Geneva CMU Rue Michel‐Servet 1 Geneva 4 CH‐1211 Switzerland
Interschool Institute of Bioengineering École Polytechnique Fédérale de Lausanne Station 12 Lausanne CH‐1015 Switzerland
Funding
HORIZON EUROPE Marie Sklodowska-Curie Actions · Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung · Werner Siemens-Stiftung
References (63)
Show source-provided references
1. 10.3389/fmicb.2016.0184110.3389/fmicb.2016.01841 ↗
2. 10.3389/fimmu.2020.0151310.3389/fimmu.2020.01513 ↗
3. 10.1084/jem.2003026610.1084/jem.20030266 ↗
4. 10.1146/annurev-immunol-020711-07502110.1146/annurev-immunol-020711-075021 ↗
5. 10.1084/jem.2008031410.1084/jem.20080314 ↗
6. 10.1038/nri315210.1038/nri3152 ↗
7. 10.3389/fimmu.2018.0032010.3389/fimmu.2018.00320 ↗
8. 10.1128/JVI.00266-1010.1128/JVI.00266-10 ↗
9. 10.1038/s41423-021-00726-410.1038/s41423-021-00726-4 ↗
10. 10.1126/sciimmunol.abi933110.1126/sciimmunol.abi9331 ↗
11. 10.1084/jem.2007089110.1084/jem.20070891 ↗
12. 10.1038/s41564-019-0506-610.1038/s41564-019-0506-6 ↗
13. 10.3389/fimmu.2019.0167710.3389/fimmu.2019.01677 ↗
14. 10.1542/peds.2014-166610.1542/peds.2014-1666 ↗
15. 10.1542/peds.2009-234510.1542/peds.2009-2345 ↗
16. 10.3310/hta1505010.3310/hta15050 ↗
17. 10.1097/QAI.000000000000224110.1097/QAI.0000000000002241 ↗
18. 10.1016/j.intimp.2020.10676010.1016/j.intimp.2020.106760 ↗
19. 10.1111/j.1476-5381.2009.00190.x10.1111/j.1476-5381.2009.00190.x ↗
20. 10.3389/fimmu.2020.0195110.3389/fimmu.2020.01951 ↗
21. 10.2217/imt.14.3710.2217/imt.14.37 ↗
22. 10.1371/journal.pone.015907410.1371/journal.pone.0159074 ↗
23. 10.1016/j.bbamem.2015.06.01510.1016/j.bbamem.2015.06.015 ↗
24. 10.1099/vir.0.038679-010.1099/vir.0.038679-0 ↗
25. 10.1021/cr000418f10.1021/cr000418f ↗
26. 10.1080/17460441.2019.157381310.1080/17460441.2019.1573813 ↗
27. 10.1021/acsnano.7b0847910.1021/acsnano.7b08479 ↗
28. 10.1002/advs.20200101210.1002/advs.202001012 ↗
29. 10.1038/nnano.2016.18110.1038/nnano.2016.181 ↗
30. 10.1038/nmat505310.1038/nmat5053 ↗
31. 10.3762/bjnano.10.10410.3762/bjnano.10.104 ↗
32. 10.1016/j.ejmech.2022.11414010.1016/j.ejmech.2022.114140 ↗
33. 10.1002/anie.20170200510.1002/anie.201702005 ↗
34. 10.1073/pnas.25047649710.1073/pnas.250476497 ↗
35. 10.1126/science.285.5428.73610.1126/science.285.5428.736 ↗
36. 10.1021/acscentsci.9b0117410.1021/acscentsci.9b01174 ↗
37. 10.1007/s00262-013-1444-410.1007/s00262-013-1444-4 ↗
38. 10.1128/JVI.79.20.12658-12666.200510.1128/JVI.79.20.12658-12666.2005 ↗
39. 10.1038/ni.185710.1038/ni.1857 ↗
40. 10.1002/cmdc.20130044510.1002/cmdc.201300445 ↗
41. 10.1126/science.120261710.1126/science.1202617 ↗
42. 10.1021/ja038223n10.1021/ja038223n ↗
43. 10.1038/s41598-018-23525-w10.1038/s41598-018-23525-w ↗
44. 10.1016/j.antiviral.2022.10538610.1016/j.antiviral.2022.105386 ↗
45. 10.1016/j.imbio.2013.06.00610.1016/j.imbio.2013.06.006 ↗
46. 10.1189/jlb.4VMR0415-160R10.1189/jlb.4VMR0415-160R ↗
47. 10.1371/journal.ppat.100104910.1371/journal.ppat.1001049 ↗
48. 10.1146/annurev-virology-122019-07002510.1146/annurev-virology-122019-070025 ↗
49. 10.1038/s41586-023-05993-x10.1038/s41586-023-05993-x ↗
50. 10.3390/v1107059610.3390/v11070596 ↗
51. 10.3389/fimmu.2021.72995110.3389/fimmu.2021.729951 ↗
52. 10.1016/j.cell.2007.09.00810.1016/j.cell.2007.09.008 ↗
53. 10.4049/jimmunol.090129610.4049/jimmunol.0901296 ↗
54. 10.3390/v306092010.3390/v3060920 ↗
55. 10.1084/jem.189.5.82110.1084/jem.189.5.821 ↗
56. 10.1371/journal.ppat.100257210.1371/journal.ppat.1002572 ↗
57. 10.1111/j.1365-2222.2008.03056.x10.1111/j.1365-2222.2008.03056.x ↗
58. Simmons R. A. · 2013
59. 10.1016/B978-0-12-818731-9.00235-410.1016/B978-0-12-818731-9.00235-4 ↗
60. 10.1128/JVI.01302-1210.1128/JVI.01302-12 ↗
61. 10.3390/v103073710.3390/v1030737 ↗
62. 10.3389/fmicb.2014.0045210.3389/fmicb.2014.00452 ↗
63. 10.1126/science.850300810.1126/science.8503008 ↗